FX.co ★ Adicet Bio Appoints Julie Maltzman As CMO

Adicet Bio, Inc. (ACET), an innovator in the development of allogeneic gamma delta T cell therapies targeting autoimmune disorders and cancer, has announced the appointment of Julie Maltzman as Chief Medical Officer, effective January 13, 2025. Maltzman will take over from Francesco Galimi, who has recently concluded his tenure with the company. Previously, Maltzman was the Chief Medical Officer at IconOVir Bio. Furthermore, she has held the position of Vice President and Global Head of GI Cancers and Cancer Immunotherapy at Roche/Genentech.